SAN DIEGO, November 13, 2018 /PRNewswire/ --
Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) researchers
"Finding potent small molecule inhibitors of NR2F6 is central to our goal of identifying and protecting the intellectual property landscape around this program. Therefore, we continue to screen for NR2F6 inhibitors using a second proprietary assay and have identified three new series of drugs that inhibit NR2F6 in a concentration-dependent manner," says Harry Lander, Ph.D., MBA, President and Chief Scientific Officer of Regen.
"As we move some of these molecules forward in our development program, we will submit the appropriate patent filings to continue to add value to the program and Regen shareholders," says David Koos, Ph.D., Chairman & CEO Regen BioPharma Inc.
The NR2F6 nuclear receptor has been identified as a potentially very important immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator. The NR2F6 small molecule program at Regen aims to identify antagonists of NR2F6 in an effort to unleash the cancer-killing potential of a patient's own immune system as well as identifying agonists which should suppress the immune system in diseases where the immune system is over-activated, such as autoimmunity.
About Regen BioPharma Inc.:
Regen BioPharma Inc. is a publicly traded biotechnology company (OTCQB: RGBP) and (OTCQB: RGBPP). The Company is focused on the immunology and immunotherapy space. The Company is focused on rapidly advancing novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is focused on small molecule therapies for treating cancer and autoimmune disorders. Additional information on Regen BioPharma is available at http://www.regenbiopharmainc.com.
Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
CONTACT INFORMATION Regen BioPharma Inc. David R. Koos, Ph.D. Chairman & Chief Executive Officer +1-619-702-1404 Phone +1-619-330-2328 Fax http://www.regenbiopharma.com email@example.com
SOURCE Regen BioPharma Inc.
Subscribe to our Free Newsletters!